Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutant RAS isoforms are prevalent oncogenes in human cancers, posing significant therapeutic challenges.
• Directly targeting mutant RAS proteins has proven difficult, despite recent advances like KRAS (G12C) inhibitors.
• Post-translational modification, specifically prenylation, is crucial for RAS function and tumorigenesis.

Purpose of the Study:

• To discuss the role of RAS proteins in human cancers.
• To explore the impact of post-prenylation carboxylmethylation on RAS-driven tumorigenesis.
• To review the effects of inhibiting isoprenylcysteine carboxylmethyltransferase (ICMT) in cancer cells.

Main Methods:

• Review of existing literature on RAS oncogenes and their role in cancer.
• Analysis of the function of isoprenylcysteine carboxylmethyltransferase (ICMT) in RAS prenylation.
• Examination of preclinical data (in vitro and in vivo) on ICMT inhibition in RAS-mutant cancer models.

Main Results:

• ICMT is the unique enzyme responsible for the final step of RAS prenylation.
• Inhibition of ICMT has demonstrated significant anti-cancer efficacy in RAS-mutant models.
• ICMT inhibition impacts cancer cells by reducing proliferation and inducing apoptosis.

Conclusions:

• Targeting ICMT represents a viable therapeutic strategy for RAS-driven cancers.
• Understanding the molecular and cellular consequences of ICMT inhibition is key to its clinical application.
• Further research into ICMT inhibitors holds promise for developing novel cancer treatments.